Company
Headquarters: San Francisco, CA, United States
Employees: 3,000
CEO: Dr. Sean Emerson George Ph.D.
$147.7 Million
USD as of Jan. 1, 2024
Company | Market Cap (USD) |
---|---|
Thermo Fisher Scientific | $219.88 B |
Danaher | $177.43 B |
Siemens Healthineers AG | $59.19 B |
Agilent Technologies, Inc. | $43.57 B |
Lonza Group Ltd | $41.66 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
Invitae Corporation has the following listings and related stock indices.
Stock: NYSE: NVTA wb_incandescent
Stock: BMV: NVTA wb_incandescent
Stock: FSX: IV8 wb_incandescent